ASPECT BIOSYSTEMS
Aspect Biosystems Ltd is an industry award winning biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering.
Founded at the University of British Columbia in Vancouver, Aspect’s disruptive 3D bioprinting platform is based on a proprietary Lab-on-a-PrinterTM technology. This technology combines and sequences complex biomaterials for broad applications in preventative health and life sciences, including regenerative medicine and orthopaedic applications.
Aspect’s technology uses a multifunctional microfluidic print head capable of programmatically manipulating and sequencing multiple biomaterials, living cells, extracellular matrix content, growth factors, bioactive compounds and other bioinks ‘on the fly’ during tissue printing.
One product that Aspect is developing is 3D printed insulin-producing beta cells. Dr Sam Wadsworth, Chief Scientific Officer, announced in 2021 that, “we have significantly advanced our development of a cell-based bio-printed pancreas therapeutic by using in vitro and in vivo studies to demonstrate long-term tissue function and efficacy in restoring blood glucose to completely normal levels in animal models of type 1 diabetes.”
Relentless team meeting with Co-Founder and CEO, Tamer Mohamed
Check out Aspect’s bioprinting process with this link.
Co-Founder and CSO, Sam Wadsworth leading a discussion on 3D printing materials structure translating into living tissue function. Human tissues on Demand … imagine the possibilities.